Key facts
- Savorease Therapeutic Foods’s last known valuation is $8.0M (May 2025).
- It has raised $2.0M.
- Notable investors include GrowthX Capital, Portland Seed Fund, State of Oregon, Built Oregon, Chemical Angel Network — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Savorease Therapeutic Foods
- ·The full record, as it builds
Funding rounds
No funding rounds for Savorease Therapeutic Foods are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Savorease Therapeutic Foods
Developer of a patented therapeutic nutrition platform designed to deliver solid supplements for dysphagia management in clinical care. The company offers clinically validated solid supplements that activate chewing motor patterns and support swallow recovery, enabling hospitals to integrate nutrition into therapy workflows and deliver safer, more effective care for patients recovering from stroke, head and neck cancer, and traumatic brain injury.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Portland, OR, United States
- Founded
- 2023
- Employees
- 5
- Website
- savorease.com/
- Ownership
- Privately Held (backing)
Savorease Therapeutic Foods doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Savorease Therapeutic Foods shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Savorease Therapeutic Foods in its N-PORT filings yet. We sweep new filings monthly.